Celgene Stock - Is Celgene Stock a Buy Today?

TL;DR

Analyzing Celgene's financial performance, acquisitions, and future outlook for potential investment.

Transcript

hey YouTube Jimmy here so in a recent video that we did to ETF's for the second half of 2018 you could see a link in the description below we got a request to do a video on cell gene now cell gene is a biotech company it's been beaten down a lot lately so I thought it would be interesting to analyze it and see if it's an opportunity or if it's some... Read More

Key Insights

• ✳️ Revlimid is crucial for Celgene's revenue, posing risks if generics enter the market.
• 📡 Acquisitions like Juno Therapeutics signal Celgene's strategy for future growth.
• ❓ R&D spending is essential but can also impact profitability.
• 🥳 Analysts use P/E ratios to estimate fair value for Celgene.
• ❓ Investor caution is advised due to industry volatility and company-specific challenges.
• ❓ Management's response to threats will influence Celgene's future performance.
• ❓ Celgene's current valuation suggests a potential investment opportunity.

Questions & Answers

Q: What is Celgene's primary revenue-generating product?

Celgene's main product, Revlimid, treats bone marrow cancer and blood disorders, contributing significantly to the company's revenue.

Q: How has Celgene responded to challenges like generic drug threats and failed drug trials?

Celgene has made acquisitions like Juno Therapeutics and focused on R&D to potentially replace revenue lost from challenges.

Q: What valuation methods can be used to assess Celgene for investment?

Analysts often use P/E multiples to value biotech stocks like Celgene, with estimates ranging around $110-$140 per share.

Q: How does investor risk factor into considering Celgene for portfolio inclusion?

Despite potential growth, volatility and ongoing challenges in the biotech industry suggest careful consideration and small position sizing for Celgene.

Summary & Key Takeaways

• Celgene, a biotech company, heavily relies on its product, Revlimid, for revenue accounting for 65% of their sales in 2017.

• Recent events like the generic version threat to Revlimid and failed drug trials have impacted Celgene's stock.

• Despite challenges, Celgene's growth potential from acquisitions and R&D may offer investment opportunities.